#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain
Peter Attia MD
A selective estrogen receptor modulator (SERM) that came to market and was observed to lower ApoB, potentially offering cardiovascular benefits, although a large outcome trial did not show event reduction in the overall population.
